MEREO BIOPHARMA GROUP PLC Financial Liabilities Reclassified Into Equity
MEREO BIOPHARMA GROUP PLC (MREO) reported Financial Liabilities Reclassified Into Equity of GBP 5.96 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-28.
Discontinued › Notes
ifrs-full:FinancialLiabilitiesReclassifiedIntoEquity · last filed 2023-03-28
| Period end | Financial Liabilities Reclassified Into Equity 6 month | Financial Liabilities Reclassified Into Equity 12 month |
|---|---|---|
| 2022-12-31 | 5.96M GBP 20-F · filed 2023-03-28 | |
| 2021-12-31 | 5.31M GBP 20-F · filed 2023-03-28 | |
| 2020-12-31 | 13.27M GBP 20-F · filed 2022-03-31 | |
| 2020-06-30 | 13.27M GBP 6-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |